These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 27900610

  • 1. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S, Roessig L, Sandner P, Lewis KS.
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [Abstract] [Full Text] [Related]

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM.
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [Abstract] [Full Text] [Related]

  • 3. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A, Castiglione V, Vergaro G, Panichella G, Senni M, Lombardi CM, Emdin M.
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [Abstract] [Full Text] [Related]

  • 4. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP, Evgenov OV.
    Handb Exp Pharmacol; 2013 Jul; 218():279-313. PubMed ID: 24092345
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS, Trochu JN, Donal E, Galinier M, Logeart D, De Groote P, Juillière Y.
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
    Correale M, Pelaggi G, Catanoso MC, Miccichè S, Teresi L, Bonanno S, Bellocchi P, Poleggi C, Capasso R, Barile M, Visco V, Carluccio E, Nodari S, Ciccarelli M, Dattilo G.
    Heart Fail Rev; 2024 Sep; 29(5):1135-1143. PubMed ID: 39044114
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A, Bowman L, D'Arsigny CL, Archer SL.
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [Abstract] [Full Text] [Related]

  • 16. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P, Berger P, Zenzmaier C.
    Gerontology; 2017 Jan; 63(3):216-227. PubMed ID: 27784018
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP.
    Handb Exp Pharmacol; 2021 Jan; 264():355-394. PubMed ID: 30689085
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
    Belenkov YN, Kozhevnikova MV.
    Kardiologiia; 2023 May 31; 63(5):68-76. PubMed ID: 37307211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.